You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


GSK, CureVac’s COVID-19 vaccine candidate shows promise in preclinical study

A preclinical study investigating CureVac’s first-generation COVID-19 vaccine candidate, CVnCoV, compared to its GlaxoSmithKline-partnered second-generation vaccine candidate, CV2CoV, has found that better activation of innate and adaptive immune responses was achieved with CV2CoV, resulting in faster response onset, higher titers of antibodies and stronger memory B and T cell activation, as compared to CVnCoV.